Das Medizinportal
Menü

Das Medizinportal

Passwort vergessen?

Bitte geben Sie Ihren Ihre E-Mail-Adresse ein. Anweisungen zum Zurücksetzen des Passworts werden Ihnen umgehend per E-Mail übermittelt.

Literatur:

Die Stieldrehung der Adnexe als gynäkologischer Notfall – Anamnese, Symptomatik, Diagnosesicherung
Paulina Dytko, Katrin A. Scherer, Matthias David 

  1. Payr E. Weitere experimentelle und klinische Beiträge zur Frage der Stieldrehung intraperitonealer Organe und Geschwülste. Langenbeck´s Archiv of Suregery/ Dt. Zeitschrift für Chirurgie 1906; 85: 392–451
  2. Sellheim H. Erklärung der Stieltorsion von Eierstockzysten. Archiv Gynäkologie 1922; 117: 27–33
  3. Robertson JJ, Ling B, Koyfman A. Myths in the evaluation and management of ovarian torsion. J Emerg Med 2017; 52: 449–456
  4. Müller F, Ulrich U. Die Adnextorsion. Frauenarzt 2011; 52: 1096–1101
  5. David M, Ebert AD. Differentialdiagnostik bei akuten Unterbauchschmerzen in der Gynäkologie. Frauenheilkunde up2date 2008; 5:4–6
  6. Chang HC, Bhatt S et al. Pearls and pitfalls in diagnosis of ovarian torsion. Radiographics 2008; 28: 1355–1368
  7. Huchon C, Fauconnier A. Adnexal torsion: a literature review. European Journal of Obstetrics & Gynecology and Reproductive Biology 2010; 150: 8–12
  8. Alcázar JL, Pascual MA et al. IOTA simple rules for discriminating between benign and malignant adnexal masses: prospective external validation; Ultrasound Obstet Gynecol 2013; 42: 467–471
  9. Huchon C, Staraci S, Farconnier A. Adnexal torsion: a predictive score for pre-operative diagnosis. Human Reproduction 2010; 25: 2276–2280
  10. Cario R. Über mechanische Ursachen der Stieldrehung von Ovarialtumoren. Zentralbl Gynecol 1891; 18: 347

Prädiktive Relevanz zirkulierender Tumorzellen im Rahmen der endokrinen Therapie beim Mammakarzinom 
Franziska Meier-Stiegen, Tanja Fehm

  1. Bidard FC, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014; 15: 406–414
  2. Janni WJ, et al. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clin Cancer Res. 2016; 22: 2583–2593
  3. Bidard FC, et al. Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy. Cancer Res. 2017; 77 (4 Supplement): S3-01-S3-01
  4. Cabel L, et al. Circulating tumor cells: clinical validity and utility. Int J Clin Oncol. 2017; 22: 421–430
  5. Selli C, et al. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res. 2016; 18: 118
  6. Maurer C, et al. New agents for endocrine resistance in breast cancer. Breast. 2017; 34: 1–11
  7. De Marchi T, et al. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer. Drug Discov Today. 2016; 21: 1181–1188
  8. Aktas B, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol. 2011; 122: 356–360
  9. Beije N, et al. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Neoplasia. 2016; 18: 647–653
  10. Babayan A, et al. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One. 2013; 8: e75038
  11. Paoletti C, et al. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res. 2015; 21: 2487–2498
  12. Paoletti C, et al. Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. Mol Oncol. 2016; 10: 1078–1085
  13. Schramm A, et al. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Arch Gynecol Obstet. 2016; 293: 271–281